免疫抑制剂使用与系统性红斑狼疮孕妇不良妊娠结局:韩国回顾性队列研究
该研究基于韩国2005-2018年国民健康保险数据库,纳入3,059名SLE女性的4,880次妊娠,评估不良妊娠结局(APO)发生率及免疫抑制剂使用模式与APO的关联。结果显示总体APO发生率为45.0%(95%CI: 43.4, 46.5%)。与持续使用羟氯喹相比,未使用、停用及妊娠期起始使用均与早产风险升高相关;孕前3个月内或孕早期暴露于致畸性免疫抑制剂与自然流产风险升高相关。
要点
- SLE孕妇总体APO发生率为45.0%(95%CI: 43.4, 46.5%)。
- 与持续使用羟氯喹相比,未使用、停用及妊娠期起始使用与早产风险升高相关。
- 孕前3个月内或孕早期暴露于致畸性免疫抑制剂与自然流产风险升高相关。
核心结论
- 从孕前至妊娠期持续使用羟氯喹可降低SLE患者早产风险。
- 孕前3个月内或孕早期暴露于致畸性免疫抑制剂增加自然流产风险。
- 研究结果强调SLE女性孕前用药规划的重要性。
研究设计与样本
- 基于韩国国民健康保险服务2005-2018年国民健康信息数据库的回顾性队列研究。
- 纳入3,059名SLE女性的4,880次妊娠。
- 估计子痫前期/子痫、早产、自然流产和死胎的发生率。
- 采用单因素和多因素模型分析孕前至妊娠期用药模式与APO的关联。
主要发现
- SLE孕妇总体APO发生率为45.0%(95%CI: 43.4, 46.5%)。
- 与持续使用羟氯喹相比,未使用与早产风险升高相关(AOR: 1.39; 95%CI: 1.05, 1.85)。
- 与持续使用羟氯喹相比,停用与早产风险升高相关(AOR: 2.18; 95%CI: 1.61, 2.95)。
- 与持续使用羟氯喹相比,妊娠期起始使用与早产风险升高相关(AOR: 2.17; 95%CI: 1.16, 4.06)。
- 孕前3个月内暴露于致畸性免疫抑制剂与自然流产风险升高相关(AOR: 2.59)。
关键数值与推荐
- 总体APO发生率:45.0%(95%CI: 43.4, 46.5%)。
- 未使用羟氯喹与早产:AOR 1.39(95%CI: 1.05, 1.85)。
- 停用羟氯喹与早产:AOR 2.18(95%CI: 1.61, 2.95)。
- 妊娠期起始羟氯喹与早产:AOR 2.17(95%CI: 1.16, 4.06)。
- 孕前3个月内致畸性免疫抑制剂暴露与自然流产:AOR 2.59;孕早期暴露:AOR 3.18。
临床怎么用
- SLE女性应从孕前开始持续使用羟氯喹并在妊娠期维持,以降低早产风险。
- 孕前应避免使用致畸性免疫抑制剂(如霉酚酸酯、甲氨蝶呤、环磷酰胺),以降低自然流产风险。
- SLE女性应在孕前进行用药规划,由风湿免疫科与产科协作管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to estimate the incidence of adverse pregnancy outcomes (APO) in patients with systemic lupus erythematosus (SLE) and to evaluate the risks associated with immunosuppressant use-including hydroxychloroquine and teratogenic agents such as mycophenolate mofetil, methotrexate and cyclophosphamide-across specific APO categories. METHODS: A cohort study was conducted using the 2005-2018 National Health Information Database of the National Health Insurance Service in Korea, involving 4,880 pregnancies in 3,059 women with SLE. The incidences of preeclampsia/eclampsia, preterm birth, spontaneous abortion and stillbirth were estimated. Associations between APOs and medication patterns from preconception through pregnancy were analysed using univariate and multivariable models. RESULTS: The overall APO incidence among pregnant women with SLE was 45.0% (95% CI: 43.4, 46.5%). Compared with continuous hydroxychloroquine use, non-use (adjusted odds ratio [AOR]: 1.39; 95% CI: 1.05, 1.85), discontinuation (AOR: 2.18; 95% CI: 1.61, 2.95), and initiation during pregnancy (AOR: 2.17; 95% CI: 1.16, 4.06) were significantly associated with increased preterm birth risk. Exposure to teratogenic immunosuppressants within 3 months of preconception or during the first trimester was associated with increased spontaneous abortion risk (AOR: 2.59 and 3.18, respectively). CONCLUSION: Continuity of hydroxychloroquine use from preconception through pregnancy reduces preterm birth risk in SLE. Conversely, early exposure to teratogenic immunosuppressants heightens the risk of spontaneous abortion. These findings underscore the importance of preconception medication planning in women with SLE.
引用
- Jung YS, Song YJ, Jang EJ, et al. Immunosuppressant use and adverse pregnancy outcomes in women with systemic lupus erythematosus: a retrospective cohort study in Korea. Rheumatology (Oxford). 2026. PMID: 41385297. doi:10.1093/rheumatology/keaf651
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。